RxDoctor Payments Data

Junaid Khan, MD

Internal Medicine · Webster, TXNPI 1578570867

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $599 of the $878 with a category attached, or 68.2%. Edwards Lifesciences accounts for 68.2% of it on its own, with 6 other manufacturers making up the rest. 2025 is the largest year on record at $599, 2.6 times the $228 reported in 2019.

$878in general payments, 2019–2025

Across 7 payments — averaging $125.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Edwards Lifesciences$599
  • Atricure, Inc.$169
  • Gotham Surgical Solutions & Devices, Inc.$44
  • Abbott$20
  • Novo Nordisk$16
  • Kowa Pharmaceuticals America, Inc.$15
  • plus $15 from 1 others
$14,374in research payments, 2019–2025

Across 1 payment — averaging $14,374 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Astrazeneca UK Limited$14K

What the payments were for

  • Consulting fees$59968%
  • Travel & lodging$16919%
  • Food & beverage$11013%

General payments by program year

19
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$878 in reported general payments places this provider in the 65th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas →

Medicare billing

Part B allowed, 2024
$390,830
Medicare patients
361
Services billed
4,971

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide101$104,000
JardianceEmpagliflozin55$52,779
EliquisApixaban38$50,663
FarxigaDapagliflozin Propanediol23$27,403
XareltoRivaroxaban22$16,456
JanumetSitagliptin Phos/Metformin Hcl14$14,281
LinzessLinaclotide11$12,364
TrulicityDulaglutide11$12,134
Trelegy ElliptaFluticasone/Umeclidin/Vilanter11$8,562
Lantus SolostarInsulin Glargine,hum.Rec.Anlog36$6,410
XanaxAlprazolam12$6,392
Repatha SyringeEvolocumab11$6,063
Levothyroxine Sodium369$4,676
Benicar HctOlmesartan/Hydrochlorothiazide12$3,560
Diltiazem 12hr ErDiltiazem Hcl11$3,036

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$16$104,000101 claims
AbbVieLinzess$15$12,36411 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Webster

See the full list for Texas →

Where these figures come from

Is this you, or does something look wrong? →